HighTower Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
HighTower Advisors's XBI Position: Q2 2026 in Review
HighTower Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q2 2026, buying an estimated $1.19M and bringing the position to 90,861 shares worth $14.4M. The position accounts for 0.01% of the portfolio, ranked #779.
HighTower Advisors first reported a position in XBI in Q2 2013 and has held it in 49 quarters since. The position peaked at $42M in Q2 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- HighTower Advisors held 90,861 shares of State Street SPDR S&P Biotech ETF worth $14.4M as of Q2 2026.
- HighTower Advisors bought 8,780 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.19M.
- State Street SPDR S&P Biotech ETF made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #779 holding.
- HighTower Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 49 quarters since.
- HighTower Advisors's State Street SPDR S&P Biotech ETF position peaked at $42M in Q2 2022.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.